Incannex expands IHL-675A indications to include COPD, asthma, bronchitis, and other inflammatory lung conditions – after receiving positive results from additional in vivo studies Feb 4, 2021 | ASX News, Incannex Healthcare (ASX:IHL)
Cholesterol-Lowering Program Delivers Two New Potent Drug Candidates May 5, 2021 | ASX News, Nyrada Inc (ASX:NYR)
Incannex to Issue Loyalty Options to Shareholders Mar 18, 2022 | ASX News, Incannex Healthcare (ASX:IHL)
Nyrada Inc (ASX:NYR) Cholesterol-Lowering Program Pathway To Phase I Dec 22, 2021 | ASX News, Nyrada Inc (ASX:NYR)